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ABSTRACT
The heterogeneous nuclear ribonucleoprotein
(hnRNP) A2 is a multi-tasking protein that acts
in the cytoplasm and nucleus. We have explored
the possibility that this protein is associated with
telomeres and participates in their maintenance. Rat
brain hnRNP A2 was shown to have two nucleic acid
binding sites. In the presence of heparin one site
binds single-stranded oligodeoxyribonucleotides
irrespective of sequence but not the corresponding
oligoribonucleotides. Both the hnRNP A2-binding
cis-acting element for the cytoplasmic RNA traf-
ficking element, A2RE, and the ssDNA telomere
repeat match a consensus sequence for binding to
a second sequence-specific site identified by muta-
tional analysis. hnRNP A2 protected the telomeric
repeat sequence, but not the complementary
sequence, against DNase digestion: the glycine-rich
domainwasfoundtobenecessary,butnotsufficient,
for protection. The N-terminal RRM (RNA recognition
motif) and tandem RRMs of hnRNP A2 also bind the
single-stranded, template-containing segment of
telomerase RNA. hnRNP A2 colocalizes with telo-
meric chromatin in the subset of PML bodies that
are a hallmark of ALT cells, reinforcing the evidence
for hnRNPs having a role in telomere maintenance.
Our results support a model in which hnRNP A2
acts as a molecular adapter between single-
stranded telomeric repeats, or telomerase RNA, and
another segment of ssDNA.
INTRODUCTION
The ends of linear chromosomes pose a problem for the DNA
replication machinery. During replication, the lagging strand
is left with a region that cannot be replicated (1,2). In the
absence of any compensatory mechanism, successive replica-
tions lead to the loss of potentially essential DNA from the
ends of the chromosomes. This shortening is minimized by
capping the chromosome ends with repetitive sequences,
TTAGGG in vertebrates (3,4) of expendable DNA. These
telomeric regions are 3–15 kb long in human somatic cells.
Progressive telomeric shortening limits the number of divi-
sions a human cell can undergo: telomere attrition is associ-
ated with chromosome instability and cellular senescence (5).
In cells of the germ line and in most cancer cells, telomere
length is preserved by the action of a reverse transcriptase,
telomerase, which consists of a protein catalytic component,
otherprotein subunits andanessentialRNA subunit(hTR) that
acts as a template for the synthesis of the telomeric repeat
DNA (6,7). Some immortalized mammalian cell lines and
tumors maintain their telomeres in the absence of telomerase
activity by one or more mechanisms referred to as alterna-
tive lengthening of telomeres (ALT) that may involve recomb-
ination and copy switching (8–10). ALT cell lines are also
characterized by the presence of novel nuclear structures, the
ALT-associated PML bodies (APBs), which contain the
promyelocytic leukemia protein (PML), telomere repeat
binding factors 1 and 2 (TRF1 and TRF2), several proteins
involved in DNA repair and recombination, and extrachromo-
somal telomeric DNA (11–13).
The double-stranded segment of telomeres, like the rest
of the genome, is wrapped up into nucleosomes formed
with histones and non-histones, and additional telomere-
speciﬁc proteins (14,15). The end portion, which includes a
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within this structure, but rather bound and protected by a
different set of proteins. The proteins bound and the conforma-
tion of the 30 overhang may vary depending on whether or not
the DNA is being actively extended by telomerase. When not
being extended, the DNA is thought to be looped back with the
overhang displacing a portion of the double-stranded telomere
and thereby forming D- and t-loops. Loop formation is pro-
moted by TRF2 (16–18) which, with TRF1, has been charac-
terized as a negative regulator of telomere length (19,20).
A number of heterogeneous nuclear ribonucleoproteins
(hnRNPs), including C1/C2 (21), D (22,23), E (24) and K
(25,26), have been reported to bind either the telomere repeat
(in vitro) or hTR (in vitro and in vivo). hnRNP A1 and UP1, its
proteolytic derivative comprising the tandem RNA recogni-
tion motifs (RRMs), bind the telomeric repeat sequence-
speciﬁcally (24,27) and protect it from nuclease digestion
in vitro (28,29). Both hnRNP A1 and UP1 also bind hTR
in vitro (30), and UP1 (but not hnRNP A1) binds the
telomerase holoenzyme (28,31). hnRNP A1 and UP1 can
bind telomerase RNA and telomeric DNA simultaneously
in vitro (30), suggesting that hnRNP A1/UP1 not only protects
the single-stranded telomeric DNA but also recruits
telomerase to telomeres (32).
Mouse and human hnRNP A2 also bind the telomeric repeat
sequence (24,33,34), as do their alternatively spliced isoforms,
B1 and B0b (35) [the latter renamed A2b (36)]. A2b also
promotes telomerase-mediated extension of a template oligo-
nucleotide in vitro. It was proposed that because the expres-
sion of hnRNP B1 is upregulated in cancer cells (37–42), the
unusually high levels of this protein may provide a mechanism
by which telomere length could be maintained, and telomerase
activity promoted inappropriately, thus allowing rapid and
ongoing division of cells (35). Recent experiments in which
small interfering RNAs were used to lower the levels of
hnRNPs A1 and A2 in several cancer cell lines, transformed
cells and normal cells reinforce the concept that these proteins
function as telomeric capping factors (43).
We show here, using pull-down and electrophoretic mobil-
ity shift assays (EMSAs), that hnRNPs A2 and A3 are the
predominant single-stranded telomere repeat binding proteins
in the rat brain. hnRNP A2 was found to possess two oligo-
nucleotide binding sites. One site binds ssDNA with little or
no nucleotide sequence preference whereas the second binds
oligoribonucleotides or oligodeoxyribonucleotides sequence-
speciﬁcally. Mutational analysis has identiﬁed a consensus
nucleotide sequence for binding to the latter site that is con-
sistent with the association with the human single-stranded
TTAGGG telomere repeat and the A2RE11 cytoplasmic
RNA trafﬁcking element (44). Using puriﬁed hnRNP A2
domains, we have established that both RRMs are required
for association with the telomeric repeat, whereas the RRM1
alone, of hnRNP A1, has been reported to sufﬁce for repeat
binding (28). Intact hnRNP A2 protein, but neither individual
or concatenated RRMs nor the Gly-rich domain (GRD), is able
to protect telomeric DNA from DNase. In contrast, the con-
catenated RRMs of hnRNP A1 are sufﬁcient for protection
from DNase (28). hnRNP A2 and its RRM concatamer also
bind the telomerase RNA, with only weak binding to the
isolated RRM1, and none to RRM2, in contrast to hnRNP
A1. Thus hnRNP A2 can potentially bind the telomeric
DNA repeat and the RNA component of telomerase simultan-
eously, or it may bind ssDNA in both sites thus acting as an
intramolecular or intermolecular cross-link. Finally, we show
for the ﬁrst time that hnRNP A2 is colocalized with TRF2 and
PML in the subset of APB nuclear bodies. These data are
consistent with a role for hnRNP A2 in protecting telomeric
DNA in vivo against nuclease digestion, and in recruiting
hTR to the telomere.
MATERIALS AND METHODS
Protein expression and purification
Human hnRNP A2 (44) and domains of this protein, residues
1–89 (RRM1), 101–179 (RRM2), 1–189 (RRM1+20) and
189–341 (GRD), were expressed in Escherichia coli and puri-
ﬁed as previously described (45). The domains were expressed
with N-terminal hexahistidine tags that were subsequently
cleaved with enterokinase, leaving each with the N-terminal
extension Ala-Met-Ala-Ile-Ser from the expression vector.
The tag was not removed from GRD. The resultant proteins
were isolated by reverse-phase high-performance liquid chro-
matography (HPLC) on a C18 column using a gradient of
acetonitrile in 0.1% triﬂuoroacetic acid (TFA), lyophilized
twice to remove TFA and allowed to refold at low con-
centration near pH 7. The identity and purity of all proteins
was established by PAGE in the presence of SDS and by
electrospray mass spectrometry on a PerkinElmer Sciex
165 spectrometer; all were judged to be better than 90% pure.
Brain protein extraction
Rat brain proteins were extracted as previously described
(46). Tissues were removed from 21-day-old Wistar rats
and placed in ice-cold extraction buffer [20 mM HEPES
(N-2-hydroxyethylpiperazine-N-2-ethanesulfonicacid),0.65M
KCl, 2 mM EGTA, 1 mM MgCl2, 2 M glycerol, 14.3 mM
b-mercaptoethanol, 8.7 mM NP-40, 12.1 mM deoxycholic
acid, 1 mM phenylmethylsulfonyl ﬂuoride and 21 mM leu-
peptin, pH 7.4] immediately prior to homogenization. The
homogenate was centrifuged at 13000 g for 40 min at 4 C
and the top two layers were removed and kept at 4 C.
Affinity isolation and analysis of nucleic acid-binding
proteins
Oligonucleotides biotinylated on the 30 nucleotide with the
following sequences (here speciﬁed only for the oligoribonuc-
leotides) were synthesized by Proligo (Singapore): ZIP, GCG
GAC UGU UAC UGA GCU GCG UUU UAC ACC CUU;
A2RE, GCC AAG GAG CCA GAG AGC AUG; A2RE11,
GCC AAG GAG CC; AURE, GUU UAU AAU UUU UUU
AUU ACU G; NS1, CAA GCA CCG AAC CCG CAA CUG;
Telo1, TTAGGG; Telo3, (TTAGGG)3; Telo6, (TTAGGG)6;
Anti6, (CCCTAA)6. Streptavidin-coated superparamagnetic
particles and magnetic particle separators were purchased
from Roche (Mannheim, Germany). For each assay 0.5 mg
of magnetic particles was incubated on ice for 10 min with
2.5 mg of biotinylated oligonucleotide in a 250 ml solution of
10 mM Tris–HCl, 1 mM EDTA and 100 mM NaCl, pH 7.5.
Unbound nucleic acid was washed off with buffer containing
10 mM Tris–HCl, 1 mM EDTA and 1 M NaCl, pH 7.5. About
5 mg of brain protein was added to 0.5 mg of the labeled
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ml of binding buffer (10 mM HEPES, 3 mM MgCl2,4 0m M
NaCl, and 5% glycerol, pH 7.5) with 10 g/l heparin added to
reduce non-speciﬁc binding. The particles were washed with
binding buffer before protein bound to the particles was
released by incubation at 65 C for 10 min in 30 ml of 0.1%
SDS, 0.5% b-mercaptoethanol and 0.01% bromophenol blue.
The resultant protein solution was electrophoresed on a
12% polyacrylamide gel containing SDS and stained with
Coomassie blue, or electroblotted onto polyvinylidene
diﬂuoride (Immobilon-P, Millipore, Bedford, MA) membrane
using Tris/glycine transfer buffer at 4 C. The antibodies used
for westerns have been described previously (47).
DNase digestion
32P-labeled oligonucleotides Telo6, (TTAGGG)6, and Anti6,
(CCCTAA)6, were puriﬁed for DNase protection assays. Fol-
lowing labeling of the DNA, 10 ml of dye (0.35% Orange G
(Sigma), 30% sucrose and 2% w/v SDS) was added and the
samples were electrophoresed on a 15 cm 20% polyacryl-
amide/7 M urea gel. Gels were subsequently exposed to X-ray
ﬁlmfor1min.Theregionofgelcorrespondingtothemajorsignal
on the autoradiograph was then excised and placed into 6 vol of
buffer(0.5 M ammoniumacetate, 10mM magnesium acetate,1
mM EDTA, pH 8, 0.1% SDS), and incubated at50 C for 30–60
min. The DNA was then puriﬁed using a QIAEX II DNA puri-
ﬁcation kit (Qiagen, Hilden, Germany).
Protein was added to buffer (10 mM HEPES, pH 7.5,
0.1 mM EDTA, 2.5 mM MgCl2, 1 mM DTT and 1g/l heparin)
to a ﬁnal vol of 10 ml prior to the addition of labeled nucleic
acid and incubation at 30 C for 30 min. Five units of deoxy-
ribonucleotidase I (DNase I; Sigma) was then added, and the
reaction volume was made up to 20 ml with DNase buffer
(10·DNasebuffer:400mMTris–HCl,pH8,100mMMgSO4,
10mMCaCl2),andincubatedat37 Cforafurther30min.The
reaction was stopped by incubation at 65 C for 10 min. About
10 ml of Orange G/SDS dye was then added, and the samples
were electrophoresed through 15 cm 20% polyacrylamide/
urea gels and the DNA was detected by autoradiography.
Human telomerase RNA transcription and binding
The hTR/pGEM-T vector containing the cDNA for human
telomerase RNA (48) was linearized and residual proteins
and salts were removed from the digested vector by ethanol
precipitation. The DNA pellet was dissolved in water and
quantiﬁed. Labeled in vitro transcriptions were performed
using Promega’s Riboprobe in vitro Transcription Systems
and
32P aUTP (PerkinElmer Life Sciences, Norwalk, CT).
Transcripts of the hTR/pGEM-T vector were obtained using
SP6 RNA polymerase and the complementary hTR transcript
was generated using the T7 RNA polymerase. To ensure the
correct size of the generated transcripts, Century Plus RNA
markers (Ambion, Austin, TX) were also used, transcribed
using the T7 RNA polymerase. Following transcription and
DNase treatment (RQ1 RNase-free DNase; Promega), the
reactions were stopped using 95% formamide/bromophenol
blue (Sigma), before electrophoresis through 5% polyacryl-
amide/urea gels and detection by autoradiography. Using the
autoradiograph and the RNA markers as a guide, slices of the
polyacrylamide/urea gel containing the desired transcript were
excised and the RNA therein was puriﬁed using a modiﬁed
version of the protocol described by Chabot (49). This entailed
placing the excised gel slice into a solution of 0.5 M ammo-
nium acetate, 1 mM EDTA (made up in DEPC-treated water)
and incubating it at 4 C overnight on a roller or at65 Cfor 1h.
The supernatant was then transferred to a fresh tube, 2 vol of
100% ethanol was added and precipitation was allowed to
proceed overnight at  20 C. The precipitate was collected
by centrifugation at 16000 g at 4 C and washed with 70%
ethanol. The resulting pellet was then air-dried, redissolved
in nuclease-free DEPC-treated water and stored at  80 C.
The binding of protein to the transcribed RNA was per-
formed in 10 ml buffer containing 10 mM HEPES, pH 7.6,
0.1 mM EDTA, 2.5 mM MgCl2, 75 mM KCl, 1 mM DTT and
1 g/l heparin. RNA was added prior to the addition of protein.
The reaction mixtures were incubated on ice for 5 min, before
the addition of 2 ml of RNA/protein gel loading buffer (30 mM
Tris–HCl, pH 7.5, 40% sucrose, 0.2% bromophenol blue,
made up in DEPC-treated water). Samples were then electro-
phoresed through non-denaturing 5% polyacrylamide gels and
autoradiographed. In some experiments the RNA was dena-
tured by heating to 95 C and then cooled immediately before
use in the binding assays.
UV-cross-linking EMSAs
Recombinant proteins were obtained as described previously
(45). About 1.5 pmol of each oligonucleotide,
32P-labeled with
T4 polynucleotide kinase (New England Biolabs, Beverly,
MA),and10pmolofeachproteinweremixedinbindingbuffer
(10 mM Tris–HCl, pH 7.5, 1 mM EDTA, 4% w/v glycerol)
with a ﬁnal volume of 15 ml, and incubated for 20 min on ice.
The reaction mixtures were then irradiated with 500 mJ of
254 nm light in a Bio-Rad GS Genelinker UV chamber. These
samples were electrophoresed on 15% SDS–polyacrylamide
gels and autoradiographed. In competition experiments, the
cold competitor (75 pmol) and radiolabeled oligonucleotide
were added prior to addition of protein.
Mutational analysis of oligonucleotide binding
The consensus sequence for binding to the speciﬁc site on
hnRNP A2 was obtained from competition UV-cross-
linking experiments performed as described above. Oligonuc-
leotides were synthesized, each containing a single nucleotide
change from the wild-type A2RE11 sequence. About 10 pmol
of recombinant hnRNP A2,
32P-labeled dA2RE11 (the oli-
godeoxyribonucleotide equivalent of A2RE11), and 50-fold
ofmutatedoligodeoxyribonucleotide(GensetOligos,Lismore,
Australia) sequence were incubated, irradiated and run on
15 cm 15% SDS–polyacrylamide gels. Starting with the
A2RE11 sequence, competition with a 50-fold excess of
each of the other three deoxynucleotides, one at a time, at
each position was examined. Binding to the speciﬁc site
was distinguished from non-speciﬁc binding by comparison
of the EMSAs with the A2RE11 mutants and with the non-
speciﬁc oligodeoxyribonucleotide dNS1.
Colocalization of PML, hTRF2 and hnRNP A2 in
cell nuclei
The localization of the three proteins PML, TRF2 and hnRNP
A2 was determined in telomerase-negative JFCF-6T.1J/1–4D
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positive JFCF-6T.1J/6B cells. Immunohistochemistry was
performed on cells ﬁxed to glass slides with 2% paraform-
aldehyde and permeabilized with methanol/acetone (1:1 v/v;
 20 C for 15 min). The primary antibodies used include a
goat polyclonal against PML (sc9862; Santa Cruz Biotechno-
logy, Inc., Santa Cruz, CA), mouse monoclonal against hTFR2
(#05-521; Upstate Biotechnology, Lake Placid, NY) and a
rabbit polyclonal against hnRNP A2/B1 (47), which were
visualized with Texas Red-, AMCA- and FITC-conjugated
donkey secondary antibodies, respectively (Jackson Immuno-
Research Laboratories, West Grove, PA). Cells were mounted
with 90% glycerol containing DABCO (Sigma) antifade.
Slides were analyzed on a Leica DMLB epiﬂuorescence
microscope with appropriate ﬁlter sets. Separate images
were taken with a cooled CCD camera (SPOT2; SciTech,
Preston South, VIC, Australia) and further processed and
merged using SPOT software.
RESULTS
hnRNP A2 has a site that binds ssDNA with little
or no sequence preference
Pull-down experiments were performed in the presence of
heparin with four different oligoribonucleotides and the
corresponding oligodeoxyribonucleotides separately immobil-
ized on superparamagnetic beads. The same molar amount of
oligonucleotide, and an excess of protein extract sufﬁcient to
saturate the binding sites on the particles, was used in each
experiment. As anticipated, hnRNP A2 was detected in the
A2RE11 and dA2RE11 pull downs, and the three oligoribo-
nucleotides with unrelated sequences did not bind hnRNP A2
in the presence of heparin (44,45). However, the other three
oligodeoxyribonucleotides also bound this protein (Figure 1),
which taken together with earlier observations indicates that it
has a site that binds ssDNA more tightly than the correspond-
ing RNA with little or no nucleotide sequence preference.
Such a site was earlier detected on recombinant hnRNP A2
expressed in bacteria, but binding of oligoribonucleotides or
oligodeoxyribonucleotides to this non-speciﬁc site was elim-
inated on addition of heparin, which minimizes non-speciﬁc
interactions (45). Similarly, hnRNP A2 was isolated from rat
tissue extracts in pull-down experiments performed in the
presence of heparin with immobilized A2RE but not with
an oligoribonucleotide with scrambled sequence (44). Thus,
some feature of the rat hnRNP A2, which may be a post-
translational modiﬁcation or association with other molecules,
greatly strengthens oligodeoxyribonucleotide binding to the
non-speciﬁc site over that manifested by the recombinant
protein.
hnRNP A2 exhibits sequence-specific binding to
single-stranded telomeric DNA
Pull-down experiments with the telomere repeat immobilized
on superparamagnetic particles isolated several proteins from
rat brain protein extracts that were not bound to particles
bearing no DNA or an oligonucleotide with scrambled
sequence (45,46) (Figure 2A). These proteins were identiﬁed
from their apparent molecularmassesonSDS–polyacrylamide
gels and by western blotting (Figure 2B) as hnRNPs A1, a
minorcomponentasjudged byCoomassieBlue R250staining,
and A2 and their less abundant isoforms, and four isoforms of
hnRNP A3 (47). These three proteins share high sequence
identity and notably the residues of hnRNP A1/UP1 identiﬁed
by X-ray crystallography as participating directly in telomeric
DNA–protein interactions (27,50) are conserved between
Figure 2. hnRNPs A1, A2, A3 and their isoforms are isolated in pull downs
with a telomeric oligonucleotide. (A) Rat brain protein extract was incubated
with superparamagnetic particles bearing no oligonucleotide (track 2), the
scrambled A2RE ribonucleotide NS1 (track 3) or d(TTAGGG)4 (track 4).
BoundproteinswereelutedusingtheSDS–gelelectrophoresissampleprepara-
tionsolution.Proteinswereseparatedona15cm12%SDS–polyacrylamidegel
andstainedwithCoomassieBlueR250.Thefourarrowsontherightindicatethe
hnRNP A3 isoforms (47) and the arrowhead indicates hnRNP A2. The masses
of standard proteins (track 1) are shown in kDa (the standards used in this
experimentsuggestthattheslowestmigratinghnRNPA3bandhasa molecular
mass over 45 kDa; however, it normally migrates with an apparent mass of 42
kDa). (B) Proteins isolated as above were separated by SDS–PAGE and elec-
troblotted onto a polyvinylidine difluoride membrane. Antibodies directed
against peptides in hnRNPs A1, A2/B1(labeled A2), B1, and the two higher
molecular weight isoforms (A3
N) and all four isoforms of hnRNP A3 (A3
C)
were used to demonstrate the presence of these proteins in the eluate (47).
Molecular masses, in kDa, are indicated on the right.
Figure 1. Rat hnRNP A2 has sequence-specific and non-specific sites for
binding oligodeoxyribonucleotides. A western blot of protein binding to oli-
godeoxyribonucleotides and oligoribonucleotides immobilized on superpara-
magnetic beads in pull-down experiments with brain protein extracts. Heparin
was added to the protein extract to suppress non-specific binding. The protein
was detected with a polyclonal primary antibody to a peptide from human/
mouse hnRNP A2, and an alkaline-phosphatase-conjugated secondary anti-
body. These oligonucleotides were: the A2RE11 trafficking element
(A2RE11 and dA2RE11, the former being the oligoribonucleotide), the AU-
rich element (AURE and dAURE), the b-actin mRNA zipcode (ZIP and dZIP)
and the non-specific sequence (44,46) (NS1 and dNS1). With the exception
of the A2RE11, which binds to a specific site on hnRNP A2, the oligo-
deoxyribonucleotides but not the oligoribonucleotides bound hnRNP A2.
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change, between hnRNPs A1 and A2. The observed binding of
the telomeric DNA repeat to both hnRNPs A1 and A2 (24,33)
is consistent with the conservation of the RNA-binding
residues on these proteins.
As noted above, hnRNPs A2 (45) and A3 (47) were previ-
ously shown to possess two sites for binding a cis-acting
cytoplasmic RNA trafﬁcking element, A2RE or A2RE11,
one speciﬁc for this oligonucleotide sequence and the other
with very weak sequence dependence. The binding of the
deoxyribonucleotide analog of A2RE11 (dA2RE11) and the
telomeric DNA repeat to the same sites on hnRNP A2 was
demonstrated in UV-cross-linking EMSAs. In these experi-
ments an excess of unlabeled competitor was added with a
ﬁxed amount of puriﬁed recombinant hnRNP A2 to labeled
dA2RE11, dNS1 [a scrambled A2RE11 sequence, CAAG-
CACCGAA; (46)] or telomeric repeat-containing sequences.
An excess of a single telomeric repeat (Telo1; Figure 3A) or a
trimer (Telo3, (TTAGGG)3; Figure 3B) abolished binding of
both dA2RE11 and dNS1. dNS1 partly competed with
dA2RE11, but less effectively with Telo1 or Telo3; and
dA2RE11 eliminated dNS1 binding but did not outcompete
either telomeric repeat sequence for the speciﬁc site. Thus,
excess of dA2RE11, Telo1 or Telo3 displace dNS1 from the
non-speciﬁc site and the telomeric repeats eliminate dA2RE11
association with both the speciﬁc and non-speciﬁc sites.
Although formally it is possible that telomeric repeat binding
to hnRNP A2 acts as an allosteric inhibitor of binding, it is
likely that they compete directly for the same site with even
the single 6-nt Telo1 binding more tightly than the A2RE11
oligodeoxyribonucleotide. Although the single and triple
telomeric repeats compete effectively with dA2RE11, the oli-
goribonucleotide A2RE11 binds more tightly than all three
oligodeoxyribonucleotides (Figure 3C).
Mutational analysis identifies a consensus hnRNP
A2-binding sequence that matches both A2RE11
and the telomeric repeat
Binding of A2RE11 and the telomeric repeat to what appears
to be the same sequence-speciﬁc site on hnRNP A2 led us to
investigate the molecular requirements for association with
this site. Using competition UV-cross-linking EMSAs we
examined the ability of a 50-fold excess of unlabeled
dA2RE11 mutated in single positions, dA2RE11 and dNS1
to compete with the radiolabeled dA2RE11 probe. Figure 4A
shows representative data. Figure 4B presents the consensus
sequence for binding. One nucleotide, G6, is absolutely
required and a further four may be one of two nucleotides.
There is no discrimination between nucleotides for 4 of the
11 positions. Parallel experiments with truncated dA2RE11
molecules had indicated that for this oligodeoxyribonucleotide
only one nucleotide could be deleted from either end without
weakening binding to hnRNP A2 (data not shown).
The sequence TTAGGGT matches the consensus sequence
exactly and the remaining four positions in the 11mer may be
ﬁlled by any deoxynucleotide or are possibly not bound to the
protein. Given the multi-functional nature of hnRNP A2—e.g.
in RNA packaging, alternative RNA splicing, telomere main-
tenance, RNA transport and translation—it is anticipated that
Figure3. ThetelomericrepeatcompetesforthehnRNPA2dA2RE11bindingsite.CompetitionUV-cross-linkingEMSAsinwhich1.5pmol
32P-labeleddA2RE11,
dNS1 or telomeric sequences (Telo1 and Telo3) were incubated with 10 pmol of purified recombinant hnRNP A2 in the presence or absence of 75 pmol unlabeled
competitor, irradiated, electrophoresed on a 15% SDS–polyacrylamide gel and autoradiographed. Telo1 (A) contains a single telomeric repeat and Telo3
(B) oligonucleotide has three repeats of the telomeric sequence [i.e. (TTAGGG)3]. (C) Competition UV-cross-linking EMSAs performed by incubating
32P end-labeled rA2RE11 and Telo1 with recombinant hnRNP A2 (10 pmol) in the presence or absence of unlabeled competitor, as above. The telomeric
DNA repeat sequence competes with dA2RE11, but weakly with A2RE11, for the binding site on recombinant hnRNP A2.
490 Nucleic Acids Research, 2005, Vol. 33, No. 2it will bind other ssDNA and ssRNA motifs speciﬁed by this
consensus sequence.
Telomeric DNA repeat binds the concatenated RRMs
Previous experiments showed that A2RE binding to hnRNP
A2 was recapitulated with the tandem RRMs with an addi-
tional 10 C-terminal residues (i.e. residues 1–189 of the rat or
human protein, RRM1+20), with little binding to the isolated
RRMs (45). A parallel result was obtained with Telo3: no
binding of the radiolabeled oligonucleotide to RRM1 was
observed, with some binding to RRM2 and much stronger
associationwith the concatenated RRMs andthe whole protein
(Figure 5). This reinforces the conclusion that the telomeric
repeat oligonucleotides and A2RE11 most likely recognize the
same sites, both speciﬁc and non-speciﬁc, on the protein and
that the C-terminal glycine-rich region is not needed for tight
(nM) binding. These results for the individual RRMs differ
from previous observations with hnRNP A1, which showed
strong binding of a decameric telomere repeat to RRM1,
weaker binding to RRM2 and the strongest association with
the RRM concatamer (UP1) (28).
hnRNP A2 protects the telomeric DNA repeat
against endonuclease digestion
The
32P-labeled telomeric repeat DNA and an oligonucleotide
with the complementary sequence were added to hnRNP A2 at
several different protein concentrations before digestion with
the endonuclease DNase I. The effects of the added protein on
the oligonucleotide stability were monitored by gel electro-
phoresis. In the absence of the hnRNP A2 both oligonuc-
leotides were largely degraded, but with increasing protein
concentrations Telo6, but not the complementary oligonuc-
leotide (Anti6), showed increasing levels of protection from
DNase action (Figure 6A). The protection of this 36-nt
molecule suggests that either multiple copies of hnRNP A2
bind or the DNA structure is such that all potential cleavage
sites are obscured by one protein molecule.
Experiments with different protein modules suggest that
the role played by hnRNP A2 in DNase protection is more
complex than simple binding of the oligonucleotide. The
Figure 5. Both RRM domains of recombinant hnRNP A2 are required for
binding the telomeric sequence. (A) Schematic representation of the
recombinant proteins used. RRM, RNA recognition motif; GRD, glycine-
rich domain. The prime indicates the presence of the additional 10 residues
(179–189) beyond the C-terminal end of RRM2 that markedly increase the
affinity of the concatenated RRMs for A2RE and A2RE11. (B) UV-cross-
linking EMSA autoradiograph generated by incubating
32P end-labeled Telo3
and equimolar concentrations of the recombinant proteins, irradiating the
mixtures and separating the proteins on a 15% SDS–polyacrylamide gel. Free
Telo3 probe is indicated at bottom left. Although the telomeric sequence does
not appear to bind RRM1, it binds RRM2 and associates more tightly with the
concatenated RRMs and the whole protein.
Figure 4. A consensus oligonucleotide sequence for binding to hnRNP A2.
(A) Point mutations were introduced into the dA2RE11 sequence at each
position by replacement of the native nucleotide with the other three,
separately generating all four oligodeoxyribonucleotides for each position.
The ability of the modified oligonucleotides to compete with the unmutated
dA2RE11 was assessed by using competition UV-cross-linking EMSAs with
recombinant hnRNP A2 in the absence of heparin. Representative results are
shown. Controls are shown on the left and the results for the mutations at
the indicated positions of the A2RE11 are shown on the right. Competing
oligodeoxynucleotideshavethepointmutationsindicatedabovetheautoradio-
graphs. (B) The wild-type dA2RE11 sequence and single-nucleotide changes
that still allow specific binding are shown along with the deduced consensus
sequence. In deriving the consensus sequence it has been assumed that
substitution at each position is without direct effect on the binding of the
non-mutated nucleotides.
Nucleic Acids Research, 2005, Vol. 33, No. 2 491RRM1+20 concatamer appears to bind almost as effectively as
the whole protein (45) and might therefore be expected to
confer protection against degradation. However, protection
was afforded only by the intact protein and not by this con-
catamer or the individual RRMs (Figure 6B), thus implicating
the glycine-rich region as a factor promoting the stability of
the oligonucleotide. But the GRD alone appeared not to pro-
tect the oligonucleotide (Figure 6C).
hnRNP A2 binds the RNA template of telomerase
In addition to binding telomeric ssDNA repeats, hnRNP A2
also binds the ﬁrst 71 nt of human telomerase RNA, the seg-
ment known to bind hnRNP A1 (30). This 50 segment of hTR
was
32P-labeled, incubated with increasing amounts of recom-
binant hnRNP A2 and separated by PAGE. In the absence of
hnRNP A2 the 71-nt RNA segment migrates in two bands with
apparent sizes of  139 nt (the anticipated size, including the
vector T7 sequence) and  280 nt (possibly arising through
dimerization or formation of secondary structures): the former
is unchanged but the latter is absent at high hnRNP A2 con-
centrations, suggesting that the more slowly migrating form of
the RNA interacts preferentially with the protein. At higher
protein concentrations, the RNA was retarded, indicating
interaction of the protein with the RNA (Figure 7A, arrow
on the right). The marked difference in RNA binding between
the samples with 2 and 5 pmol of hnRNP A2 suggests cooper-
ative binding: a similarly abrupt shift in binding with
increasing protein concentration has been observed for the
binding of hnRNP A1 RRM1 to the (TTAGGG)10 DNA
oligonucleotide (30).
The speciﬁcity of the protein–RNA interaction was demon-
strated by the lack of protein binding to the heat-denatured
RNA (Figure 7B). The denatured RNA was almost entirely the
faster, possibly monomeric, form shown not to bind to the
protein. The small amount of the slower migrating RNA
remaining after denaturation was retarded by hnRNP A2:
this is faintly visible in the right-hand track of Figure 7B
(arrow on the left). Little RNA binding to RRM2 was evident
in UV-cross-linking EMSAs performed with the expressed
modules of hnRNP A2, but binding to RRM1 matched that
of the tandem RRMs (Figure 7C).
hnRNP A2 is preferentially localized with PML
and TRF2 in APBs
To date, there have been no reports of colocalization in vivo of
hnRNP proteins and telomeric DNA although hnRNP C1/C2
Figure 6. Recombinant hnRNP A2 protects telomeric DNA against DNase
digestion. (A) Increasing concentrations of recombinant hnRNP A2 (1, 4 and
10 mM) were incubated with the
32P end-labeled hexameric telomeric DNA
repeat [Telo6, (TTAGGG)6], or the complementary sequence [Anti6,
(CCCTAA)6], before adding the endonuclease DNase I. Breakdown products
of the oligonucleotides were separated on a 20% polyacrylamide/7 M urea gel.
BotholigonucleotidesareextensivelydegradedintheabsenceofhnRNPA2.In
the presence of this protein the telomeric sequence (left panel), but not the
complementarysequence(right),isresistanttoendonucleasedigestion.(B)The
GRD ofhnRNP A2is necessarybutnotsufficient forDNaseI protection.Each
recombinant protein (10 mM of RRM1, RRM2, RRM1+20 or hnRNP A2) was
assessed for its ability to protect the telomeric DNA. The proteins were
incubated with
32P end-labeled Telo6 or Anti6 before adding DNase I. Break-
down products of the oligonucleotides were separated on a 20% polyacryl-
amide/7 M urea gel and visualized by autoradiography. The individual or
concatenated RRMs provided no protection: the intact protein was required,
suggesting that the glycine-rich region is involved in protecting the telomeric
sequence against enzymatic degradation. The telomeric sequence, but not its
complement,isprotected.(C)DNaseIprotectionassayperformedasdescribed
above, using 1, 4 and 10 mM of the recombinant GRD protein. This domain
appears to be necessary but not sufficient for RNA protection.
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both of which are primarily telomere-associated proteins (21).
Examination of metaphase spreads of telomerase-positive and
telomerase-negative human ﬁbroblast lines by immunostain-
ing with antibodies to hnRNP A2 followed by ﬂuorescence
in situ hybridization for telomeric DNA frequently showed
localization of hnRNP A2 at telomeres (data not shown),
but the protein could not be detected consistently, possibly
indicating that the amount of protein is at the limit of detection
with these antibodies. Immunoﬂuorescence staining of human
ﬁbroblasts with antibodies to hnRNP A2, TRF2 and PML
showed that these proteins colocalized in APBs (Figure 8).
These structures are found only in telomerase-negative cell
lines and tumors that use the ALT mechanism of telomere
maintenance, and are a subset of the PML nuclear bodies
that are characterized by the presence of extrachromosomal
telomeric DNA, telomere binding proteins, such as TRF1 and
TRF2, and other proteins involved in recombination and DNA
repair(11). These invivoobservations thus supportour in vitro
demonstration of speciﬁc interactions between hnRNP A2 and
the telomeric DNA repeat sequence.
DISCUSSION
Many proteins are involved in the synthesis and maintenance
of telomeres. They include Pot1, which binds the G-rich telo-
mere end (51), and TRF1 and TRF2, which bind double-
stranded telomeric DNA (16). These proteins are negative
regulators of telomere extension. Loss of TRF2 leads to
cell-cycle arrest, apoptosis (52) and end-to-end ligation of
telomeres (53). Other proteins associated with TRF1, TRF2
or the ssDNA repeats have been identiﬁed, including several
members of the hnRNP family. The roles of the hnRNPs in
telomere biology are not well established but if, as proposed,
some recruit telomerase to the chromosome ends they would
be expected to support telomere extension, with diminished
protein expression resulting in telomere shortening.
The hnRNP A/B proteins are abundant in many cell types.
They are localized primarily to the nucleus where they may
bind the telomeric DNA repeat (24,33–35) and participate in
telomere maintenance. They are also involved in packaging
nascent mRNA, in alternative splicing (24,54–56), and in
cytoplasmic RNA trafﬁcking (44,46), translation (57) and
stabilization (58,59). In each role they presumably interact
with sets of molecules that incorporate different RNA or
DNA elements.
Figure 8. hnRNP A2/B1, PML and TRF2 are colocalized in nuclear bodies.
Colocalization of hnRNP A2/B1, PML and hTRF2 at APBs in the nuclei of
telomerase-negative, immortalized human fibroblasts (JFCF-6T.1J/1–4D
cells). (A) hnRNP A2/B1 (FITC, green). (B) PML (Texas Red, red). (C)
TRF2 (AMCA, blue). (D) Colocalization is indicated by the arrows in the
merged image. Scale bar: 10 mm.
Figure 7. hnRNP A2 binds the first 71 nt of human telomerase RNA.
(A)
32P-labeled hTR 50 71-nt was incubated with increasing amounts (0, 0.1,
0.5, 1, 2, 5 and 10 pmol) of recombinant hnRNP A2, and separated on a 15-cm
5%polyacrylamidegel.Theseassayswereperformedinthepresenceof1mg/ml
heparin. The arrow on the right marks the retarded RNA–protein complex.
(B) Assay was performed as above, except that the RNA used was first dena-
tured by heating to 95 C for 5 min, cooled by placing immediately on ice and
then incubated with protein. (C)
32P-labeled hTR 50 71-nt RNA was incubated
with 1, 10 and 100 mM of each recombinant protein, and separated on a 15-cm
5% native polyacrylamide gel. The single and double arrowheads point to the
monomer and dimer forms of the RNA, respectively.
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A3, and their isoforms, were isolated in our pull-down experi-
ments with the telomeric repeat. In the rat brain, hnRNPs A2
and A3 are the predominant binding proteins. These proteins
share high sequence identity, with hnRNPs A3 and A1 being
more closely related than hnRNPs A2 and A1. Over the
tandem RRM region they have  80% sequence identity and
hence hnRNPs A2 and A3 are likely to share the typical RRM
babbab fold of hnRNP A1 (60). The crystal structure of the
UP1 proteolytic fragment of hnRNP A1 (residues 1–196 of the
human protein) complexed to the single-stranded telomeric
repeat [d(TTAGGG)2] (50) shows that the amino acid residues
of hnRNP A1 that interact with the oligodeoxyribonucleotide
are present in hnRNP A2, with the exception of a single Lys to
Arg substitution. Because only the main chain atoms of this
residue,K183, interact with G11, it isunlikelythat substitution
with arginine would interfere with the interaction between
hnRNP A2 and the telomeric repeat. Despite this conservation
of interacting residues, there are differences in the binding of
the telomeric repeats by hnRNPs A1 and A2, as discussed
below.
In an earlier study we presented evidence from EMSA and
biosensor data that recombinant hnRNP A2 has two sites that
bind oligoribonucleotides or oligodeoxyribonucleotides, but
with this protein only the sequence-speciﬁc site was occupied
in the presence of heparin (45). In contrast, we discovered in
this study that rat hnRNP A2 also has two sites but binds
oligodeoxyribonucleotides at the non-speciﬁc site even in
the presence of heparin (Figure 1). Possession of two sites
raises the possibility of the protein acting as a non-covalent
cross-linker of nucleic acids. DNA or RNA molecules (con-
taining e.g. the telomere repeat or A2RE11) occupying the
speciﬁc site may be linked to any other ssDNA. The ability to
bind the telomeric repeat at both sites may also be important
for protection of the ssDNA from nuclease activity.
Although the telomere repeat binds the isolated RRM1 of
hnRNP A2 weakly (if at all) and isolated RRM2 somewhat
more strongly, the tandem extended RRMs (residues 1–189)
are needed for binding that matches the whole protein. This
binding pattern deviates from that for hnRNP A1, the ﬁrst
RRM of which was found to bind more tightly than RRM2
(28). RRM1 is sufﬁcient for A1/UP1binding to a telomeric
DNA oligonucleotide (30). This difference points to the
divergence in the mode of interaction for hnRNPs A1 and
A2, with the latter possibly not mimicking the anti-parallel
dimeric molecular arrangement observed in the crystalline
state, in which oligonucleotides bind RRM1 of one hnRNP
A1 molecule and RRM2 of the other.
The requirements in the nucleic acid for binding to the
sequence-speciﬁc site of hnRNP A2 were established by muta-
tional analysis, starting with A2RE11. This led to a consensus
sequence that includes the telomeric sequence (Figure 4) and
the hnRNP A1-binding d(GGCAG) tandem repeats of the
mouse hypervariable minisatelite (29). Changes in a single
nucleotide have been shown to markedly alter oligonucleotide
binding to hnRNP A2 (Figure 4) and UP1 (27). As a
consequence of the redundancy at several positions in the
consensus sequence, it can give rise to many different oligo-
nucleotides. hnRNP A2, a recognized multi-tasking protein
(61), may therefore potentially interact with numerous differ-
ent RNA or DNA elements, thereby inﬂuencing many
metabolic or signaling pathways. Moreover, it could act as
the link between pathways utilizing nucleic acids that compete
for binding to its RRMs.
UP1bindsthetelomericrepeatsequencespeciﬁcallyinvitro
(28), protecting it from degradation by nucleases, and
demonstrates helix-unwinding ability (62). UP1 also binds
the telomerase holoenzyme in vitro, promoting telomere
extension at low concentrations (31), but inhibiting it at higher
concentrations (28). Inaddition,both hnRNPA1 andUP1 bind
telomerase RNA and telomeric DNA simultaneously in vitro
(30), and may thus be capable of recruiting telomerase to form
part of the protective complex on telomere ends.
The segment of hnRNP A2 equivalent to UP1, UP1-B
(which is contained within RRM1+20), is necessary and suf-
ﬁcient to bind the telomeric sequence in vitro but it did not
mirror the behavior of UP1: in our experiments it did not
protect the telomeric DNA (Figure 6A). Protection against
endonuclease-catalyzed degradation required the whole pro-
tein, suggesting that the glycine-rich C-terminal domain of
hnRNP A2 plays a critical role in this action (Figure 6B).
Protection in vivo is also provided by other telomere-
associated molecules that bind to multiple sites, such as
Pot1 (51).
hnRNP A2 retarded the 50 71-nt segment of hTR in an
EMSA (Figure 7A). This includes the template region
which is within the single-stranded region (63) that is most
likely to bind hnRNP A2. The apparent binding of hnRNP A2
to dimers, rather than monomers, of the 50 71-nt hTR segment
(Figure 7) may not faithfully recapitulate the molecular inter-
actions in vivo, but functional telomerase is dimeric and
includes two RNA molecules that cooperate functionally
(64,65).
FisetandChabot(30)earlierproposed thathnRNPA1could
simultaneously bind telomerase, through interaction with its
RNA, and the telomeric DNA repeat, thus providing a mech-
anism for recruitment of telomerase to the chromosome ends
(32). Our observation that hnRNP A2 has two binding sites for
single-stranded oligonucleotides leads to a parallel conclusion
but, based on current evidence, the molecular mechanisms
differ for these two proteins. The sites on hnRNP A1 for
the telomericDNA repeat andtelomerase RNA were identiﬁed
as residing on RRM1 and RRM2, respectively, whereas both
RRM modulesofhnRNPA2areneededfortightbindingtothe
repeat. RRM1 and the tandem RRMs of hnRNP A2 bind the
71-nt RNA segment, whereas no binding of RRM2 was appar-
ent (Figure 7C). The telomerase RNA is therefore unlikely to
beboundtothenon-speciﬁchnRNPA2site,which appearsnot
to bind oligoribonucleotides strongly (Figure 1), nor does it
bind the entire sequence-speciﬁc site, which spans the tandem
RRMs. Further investigation is needed to establish whether its
association with RRM1 makes use of part of the sequence-
speciﬁc site.
In the mouse erythroleukemic cell line CB3 (66), there is no
measurable hnRNP A1 expression and the terminal repeat
DNA fragments are markedly shorter than those in the similar
cell line, CB7, which expresses hnRNP A1 (31).But even after
multiple passages of CB3, the mean terminal repeat fragment
length did not change signiﬁcantly, indicating that although
hnRNP A1 may be required for full telomerase-mediated
extension, in its absence another protein (or proteins) can
prevent degradation of the telomere. On the basis of the results
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protein can fulﬁll some or all of these functions.
Interestingly, hnRNP A2 and TRF2 are both present at
higher than background levels in APBs. These intranuclear
domains, which contain extrachromosomal telomeric DNA
and telomere-speciﬁc binding proteins together with PML
proteins, are speciﬁc for ALT-positive cell lines (11). Their
function is unknown, but it has been proposed that they might
be depots of telomeric DNA and associated proteins required
for ALT, or function as platforms for the ALT process.
Telomeric DNA is not associated with the PML bodies of
telomerase-positive cell lines and it is absent from many
PML bodies within ALT cell nuclei, i.e. APBs are a subset
of the PML bodies in ALT cells. The presence of hnRNP A2 in
APBs (but not in PML bodies that do not contain telomeric
DNA) suggests that telomeric chromatin is sufﬁcient for the
localization of hnRNP A2, and that hTR and telomerase activ-
ity are not required. hnRNP A2 was not present in every APB,
consistent with the possibility that some aspect of the state of
the telomeric chromatin is responsible for hnRNP A2 local-
ization. It will be of interest to determine whether there are
interactions among the hnRNPs and other proteins, such as
Pot1 (51), that protect the telomere ends from degradation.
In conclusion, from our studies it is evident that hnRNP A2
binds in a complex fashion to ssDNA and ssRNA. We found
that rat brain hnRNP A2 has two sites for binding oligonuc-
leotides.Onebindsoligodeoxyribonucleotidesinpreferenceto
oligoribonucleotides and shows little discrimination between
diverse sequences. The second, which requires both RRMs,
has been shown to bind to sequences deﬁned by the consensus
sequence N(A,C,T)(C,T)(A,T)(A,G)G(C,G,T)(A,T)NNN: this
sequence encompasses the telomeric repeat sequence. In
addition, the template-containing segment of telomerase
RNA binds to RRM1, raising the possibility that it competes
with the ssDNA telomeric repeat for the hnRNP A2 sequence-
speciﬁc site. As the G-rich overhanging strand lengthens, it
may compete more effectively with telomerase RNA for bind-
ing to RRM1, displacing the RNA and thus limiting the
telomerase-mediated strand extension. Although hnRNP A2
binds telomerase RNA, the preferential localization of hnRNP
A2 with TRF2 in APBs suggests that telomerase is not needed
for association with telomeric DNA. Combined with our
in vitro binding data, the localization in APBs suggests an
important role for this protein in telomere maintenance.
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